Miao Qing-fang, Shao Rong-guang, Zhen Yong-su
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.
Yao Xue Xue Bao. 2012 Oct;47(10):1261-8.
The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Approximate 17 monoclonal antibodies have been approved as cancer therapeutics since 1997. Antibody-drug conjugates (ADC) are powerful new treatment options for cancer, and naked antibodies have recently achieved remarkable success. The safety and effectiveness of therapeutic mAbs in oncology vary depending on the nature of the target antigen and the mechanisms of tumor cell killing. This review provides a summary of the current state of antibody-based cancer therapy, including the mechanisms of tumor cell killing by antibodies, tumor antigens as antibody targets, clinical effectiveness of antibodies in cancer patients and nanoparticles-based ADCs.
近年来，单克隆抗体（mAbs）在癌症治疗中的应用取得了显著成功。自1997年以来，约有17种单克隆抗体被批准用于癌症治疗。抗体药物偶联物（ADC）是强大的新型癌症治疗选择，而裸抗体最近也取得了显著成功。治疗性单克隆抗体在肿瘤学中的安全性和有效性因靶抗原的性质和肿瘤细胞杀伤机制而异。本综述总结了基于抗体的癌症治疗的现状，包括抗体杀伤肿瘤细胞的机制、作为抗体靶点的肿瘤抗原、抗体在癌症患者中的临床疗效以及基于纳米颗粒的ADC。
